News Jemperli label extended to include rectal cancer GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as the first pre-operative cancer immunotherapy for rectal cancer.
News Trodelvy gets EU nod for first-line triple-neg breast cancer A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
News GSK to file Jemperli for rectal cancer after phase 3 readout GSK's pivotal AZUR-1 trial of Jemperli monotherapy to delay or eliminate surgery in pre-operative rectal cancer has delivered a positive result.
Oncology ASCO 2026: A potential functional cure in endometrial cancer... For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep.
News GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
News GSK unit and AnaptysBio trade lawsuits over Jemperli A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
